ESTEVE CDMO, Esteve's Healthcare contract development and manufacturing organization, is strengthening its global manufacturing footprint through the relocation, expansion and modernization of its existing operations in China, with an investment of more than $80 million.
The new facility in Shaoxing significantly expands ESTEVE CDMO's manufacturing capabilities in Asia, combining increased capacity, advanced technologies, and flexibility for future growth. It complements the company's established manufacturing network across Europe, the Americas and Asia, strengthening its ability to support pharmaceutical partners worldwide.
"This investment is an important step in the sustained growth of ESTEVE CDMO and our global manufacturing platform. Strengthening our presence in China allows us to bring our capabilities closer to customers in Asia while leveraging the expertise of our global network. Our ambition is clear: to build a leading global CDMO business with the capabilities and flexibility to support our partners worldwide. This is what drives us: making a difference for patients and contributing to our shared purpose of improving lives together," said Joan Petit, ESTEVE CDMO President.
Increased capacity and advanced capabilities
The facility includes three manufacturing workshops with a total reaction volume of 250 m³. The facility has been designed with space reserved for an additional 150+ m³, allowing potential total reaction volume to reach 400+ m³ as manufacturing needs evolve. The site includes the necessary service and utility infrastructure to support this future capacity.
Advanced manufacturing, automation and digitalization are integrated throughout the facility, including a purpose-built centralized control center, alongside warehousing facilities, an office building and dedicated infrastructure. This design provides flexibility to expand capacity in line with customer and market needs.